Litcius/Paper detail

Pt(<scp>iv</scp>) antitumor prodrugs: dogmas, paradigms, and realities

Mauro Ravera, Elisabetta Gabano, Michael J. McGlinchey, Domenico Osella

2021Dalton Transactions67 citationsDOI

Abstract

) tested. Here, we summarize the recent progress in the development and understanding of the chemical properties and biochemical features of these Pt(IV) prodrugs, especially those containing bioactive molecules as axial ligands, acting as multi-functional agents. Even though no such prodrugs have been yet approved for clinical use, many show encouraging pharmacological profiles. Thus, a better understanding of their features is a promising approach towards improving the available Pt-based anticancer agents.

Topics & Concepts

ProdrugChemistryPharmacologyCombinatorial chemistryStereochemistryBiochemistryMedicineMetal complexes synthesis and propertiesRadiopharmaceutical Chemistry and ApplicationsDNA and Nucleic Acid Chemistry
Pt(<scp>iv</scp>) antitumor prodrugs: dogmas, paradigms, and realities | Litcius